This invention provides for compounds of the formula:

##STR00001##

wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

An organic compound has a benzonaphthofuran skeleton and is represented by General Formula (G1). In General Formula (G1), A represents a pyrene skeleton. In the case where the pyrene skeleton has a substituent, the substituent is a diarylamino group including two substituted or unsubstituted aryl groups each having 6 to 13 carbon atoms, a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, an alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted monocyclic saturated hydrocarbon group having 3 to 20 carbon atoms, or a substituted or unsubstituted polycyclic saturated hydrocarbon group having 7 to 10 carbon atoms. The two aryl groups of the diarylamino group may be the same or different. In X1 represented by General Formula (G1-1), one of R6 and R7 is bonded to N in General Formula (G1), and the other of R6 and R7 represents an alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted monocyclic saturated hydrocarbon group having 3 to 20 carbon atoms, or a substituted or unsubstituted polycyclic saturated hydrocarbon group having 7 to 10 carbon atoms.

An organic compound has a benzonaphthofuran skeleton and is represented by General Formula (G1). In General Formula (G1), A represents a pyrene skeleton. In the case where the pyrene skeleton has a substituent, the substituent is a diarylamino group including two substituted or unsubstituted aryl groups each having 6 to 13 carbon atoms, a substituted or unsubstituted aryl group having 6 to 13 carbon atoms, an alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted monocyclic saturated hydrocarbon group having 3 to 20 carbon atoms, or a substituted or unsubstituted polycyclic saturated hydrocarbon group having 7 to 10 carbon atoms. The two aryl groups of the diarylamino group may be the same or different. In X1 represented by General Formula (G1-1), one of R6 and R7 is bonded to N in General Formula (G1), and the other of R6 and R7 represents an alkyl group having 1 to 7 carbon atoms, a substituted or unsubstituted monocyclic saturated hydrocarbon group having 3 to 20 carbon atoms, or a substituted or unsubstituted polycyclic saturated hydrocarbon group having 7 to 10 carbon atoms.

The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

##STR00001##

The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.

The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.

Provided is a novel compound capable of improving the luminous efficiency, stability and lifespan of a device, an organic electronic device using the same, and an electronic device.

Provided is a novel compound capable of improving the luminous efficiency, stability and lifespan of a device, an organic electronic device using the same, and an electronic device.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.